Clinical Trial: Phase 3 Study of the Safety, Tolerability, and Efficacy of ALK-001 on the Progression of Stargardt Disease

U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07419334) titled 'Phase 3 Study of the Safety, Tolerability, and Efficacy of ALK-001 on the Progression of Stargardt Disease' on Feb. 10.

Brief Summary: This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Stargardt Disease

Intervention: DRUG: ALK-001

Daily oral administration for 24 months

DRUG: Placebo

Daily oral administration for 24 months

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Alkeus Pharmaceuticals, Inc.

Publ...